NIH Reporter #1R44CA310364-01

Award for Development of Gene Expression Assay for Lymphoma Diagnosis – National Cancer Institute

This award from the National Cancer Institute (NCI), under the U.S. Department of Health and Human Services, supports the development of a gene expression assay to enhance lymphoma diagnosis. - Government Buyer: - National Cancer Institute (NCI), U.S. Department of Health and Human Services - Products/Services Requested: - Gene expression assay development for lymphoma diagnosis - Validation studies for the developed assay - Regulatory submission support for the assay - Estimated Contract Value: - $1,770,000 - Requirements: - Bidders must demonstrate experience in gene expression assay development - Compliance with NIH guidelines is mandatory - Work to be performed primarily in Boston, MA - Classification: - NAICS Code 541714 (Research and Development in Biotechnology) - PSC Code 6550 (Medical and Surgical Instruments, Equipment, and Supplies) - No specific OEMs or vendors are named in the notice

Description

This solicitation is for the development of a cost-effective gene expression assay aimed at improving lymphoma diagnosis accuracy and speed. The project includes gene expression assay development, validation studies, and regulatory submission support. Bidders must demonstrate experience in gene expression assay development and adhere to NIH guidelines. The work is to be performed primarily in Boston, MA, with a pre-bid meeting held in Bethesda, MD.

View original listing